Veterinary Industry Revenue and Employment
The global veterinary services market generated an estimated $35 billion in revenue in 2023, with the United States accounting for roughly 35% of that total. The American Veterinary Medical Association reported 124,000+ veterinarians actively practicing in the U.S. as of 2023, with companion animal medicine representing the largest revenue segment. Employment in veterinary services grew faster than the overall U.S. labor market over the past decade, driven by rising pet ownership and increased spending per animal. The U.S. Bureau of Labor Statistics projects continued demand as pet humanization trends persist across urban and suburban markets.
Vet facts show that corporate veterinary chains now operate thousands of clinics across the U.S., with the top five companies managing a growing share of the market. Mars Veterinary Health, a division of Mars Inc., operates more than 2,500 hospitals and clinics worldwide and is one of the largest veterinary services providers globally. The company's scale and centralized purchasing power influence pricing, drug supply chains, and diagnostic equipment standards across the industry. Independent practices still represent the majority of clinics, but corporate-affiliated locations have expanded their share of total revenue in recent years.
Public Companies and Financial Performance
Several publicly traded companies dominate the veterinary services and products space, with their financials tracked by investors and analysts. Mars Inc. remains privately held, but its veterinary division is frequently cited in industry reports as a benchmark for revenue scale and geographic reach. VCA Inc., which operates over 1,000 animal hospitals in North America, was acquired by Mars in 2017, consolidating a significant portion of the U.S. referral and general practice market under one corporate umbrella. Forbes coverage of the veterinary sector's growth and investment trends highlights the shift toward consolidated, tech-enabled care models.
Vet facts from SEC filings show that publicly traded veterinary product companies focus on pharmaceuticals, diagnostics, and medical devices for companion animals and livestock. Covetrus, a major veterinary pharmaceuticals and distribution company, reported its financial results through public filings, with revenue driven by distribution of prescription drugs, vaccines, and health products. SEC EDGAR filings for Covetrus provide detailed breakdowns of revenue by segment, geographic exposure, and risk factors affecting the veterinary supply chain. Investors use these filings to track margins, R&D spending, and exposure to regulatory changes in animal health product approvals.
Regulatory and Market Structure
The veterinary industry is regulated by a mix of federal and state agencies that oversee drug approvals, practice standards, and facility licensing. The U.S. Food and Drug Administration's Center for Veterinary Medicine approves animal drugs and monitors safety, while state veterinary medical boards license practitioners and enforce practice acts. FDA Center for Veterinary Medicine publishes data on approved animal drug products, recalls, and residue tolerances that directly affect pharmaceutical revenue and market access. Vet facts indicate that the approval pipeline for new animal drugs has grown, with increased focus on oncology, pain management, and chronic disease treatments for companion animals.
Market structure data show that the veterinary sector remains fragmented at the practice level but concentrated at the corporate and supply-chain levels. The American Animal Hospital Association accredits hospitals based on standards for care, facilities, and medical protocols, creating a quality benchmark that influences client choice and insurance reimbursement. American Animal Hospital Association publishes accreditation data and hospital search tools